Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SVRA
SVRA logo

SVRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Savara Inc (SVRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.460
1 Day change
8.12%
52 Week Range
7.000
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Savara Inc (SVRA) is not a strong buy for a beginner investor with a long-term strategy at this moment. The stock lacks clear positive catalysts, and technical indicators are neutral. While insider buying is a positive sign, the financial performance and lack of significant news or analyst upgrades do not support a compelling long-term investment case right now. A hold position is recommended until stronger signals emerge.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 53.093, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 5.155, with resistance at 5.422 and support at 4.887.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The Put-Call ratios suggest bearish sentiment in the short term, with higher put volume relative to calls. Implied volatility is high at 421.31, indicating significant uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
10

Positive Catalysts

  • Insiders are buying, with a 373.33% increase in buying activity over the last month.

Neutral/Negative Catalysts

  • No recent news or significant events to drive the stock higher. The financials show no revenue growth and a net income loss of -$32.24M in Q4 2025.

Financial Performance

In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved by 10.99% YoY but remains negative at -$32.24M. EPS is -0.13 with no YoY growth. Gross margin is 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target updates are available.

Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
Wall Street analysts forecast SVRA stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
sliders
Low
9
Averages
10.17
High
11
Current: 5.050
sliders
Low
9
Averages
10.17
High
11
H.C. Wainwright
Andrew Fein
Buy
maintain
$8 -> $10
AI Analysis
2025-12-23
Reason
H.C. Wainwright
Andrew Fein
Price Target
$8 -> $10
AI Analysis
2025-12-23
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on Savara to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.
Oppenheimer
Oppenheimer
Outperform
maintain
$8 -> $9
2025-11-14
Reason
Oppenheimer
Oppenheimer
Price Target
$8 -> $9
2025-11-14
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Savara to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a more than $1B opportunity for MOLBREEVI in aPAP following recent updated claims data giving line of sight to at least 1,000 patients by launch with 750 already identified.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SVRA
Unlock Now

People Also Watch